恒瑞医药(600276.SH)：HRS-8364片获准开展临床试验

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of HRS-8364 tablets, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Group 1 - The company has announced the approval of a clinical trial for HRS-8364 tablets [1] - HRS-8364 is an innovative anti-tumor drug developed independently by the company [1] - The clinical trial is set to commence in the near future [1]